Evotec (NASDAQ:EVO) has secured two new grants from the Bill & Melinda Gates Foundation totaling $9.9 million, aimed at accelerating the discovery and development of next-generation treatments for tuberculosis (TB).
The funding will support a 24-to-25-month program focused on identifying novel small molecules and evaluating advanced drug combinations.
The Hamburg-based company will leverage its proprietary AI-enabled drug discovery platform to streamline the identification of candidates that can treat both standard and drug-resistant forms of the disease.
A primary goal of the research is to de-risk the transition from laboratory settings to clinical testing, addressing a critical bottleneck in global health R&D.
A significant portion of the grants will fund the nonclinical evaluation of advanced regimens, including Long-Acting Injectables (LAIs).
These formulations are viewed as a potential "game-changer" for TB therapy, as they could replace burdensome daily oral pill cycles with less frequent dosing, significantly improving patient adherence and reducing the risk of treatment failure.
TB remains one of the world's deadliest infectious diseases, exacerbated by the rise of multi-drug resistant strains.
By integrating AI-driven insights with nonclinical efficacy and resistance data, Evotec aims to deliver "pan-TB" regimens that are effective against all forms of the disease.